BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
BeyondSpring Inc. announced a poster presentation at the 2026 ASCO Annual Meeting showcasing Study 303, a Phase 2 investigator-initiated trial investigating the efficacy and safety of a triple combination therapy of plinabulin, docetaxel, and pembrolizumab in metastatic non-small cell lung cancer (NSCLC) patients resistant to PD-1/PD-L1 inhibitors.…